Among these, miR-122, which negatively regulates hepatic lipogenesis, is reduced in NASH patients [66] whereas miR-34a, that induces β-oxidation and inhibits synthesis of fatty acids via a sirtuin1/5′ adenosine monophosphate-activated protein kinase/3-hydroxy-3-methylglutaryl-CoA reductase (SIRT1-AMPK-HMGCR) mechanism, is upregulated in NAFLD patients [67]. The gene discussed is SIRT1; the disease is metabolic dysfunction-associated steatotic liver disease.